Catalog No.
YHH72401
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Met22-Pro141
Predicted molecular weight
15.37 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q495A1
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
VSTM3, TIGIT, V-set and transmembrane domain-containing protein 3, VSIG9, V-set and immunoglobulin domain-containing protein 9, T-cell immunoreceptor with Ig and ITIM domains
Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity. PMID: 29500245
Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes. PMID: 32903786
A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade. PMID: 32782142
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. PMID: 19011627
The TIGIT/CD226 axis regulates human T cell function. PMID: 22427644
TIGIT Blockade: A Multipronged Approach to Target the HIV Reservoir. PMID: 32432050
Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8(+) T Cells. PMID: 30555485
A Novel d-Peptide Identified by Mirror-Image Phage Display Blocks TIGIT/PVR for Cancer Immunotherapy. PMID: 32386245
TIGIT limits immune pathology during viral infections. PMID: 32152316
Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy. PMID: 33298247
TIGIT predominantly regulates the immune response via regulatory T cells. PMID: 26413872
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. PMID: 31238970
CTLA-4: a moving target in immunotherapy. PMID: 29118008
Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. PMID: 21199897
Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies. PMID: 33277440
Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas. PMID: 33158916
Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer. PMID: 32716559
Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. PMID: 28623459
TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro. PMID: 32804915
PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy. PMID: 33188038
Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. PMID: 24745333
For research use only. Not for human or drug use.
